title: Adherence to adalimumab in patients with moderate to severe psoriasis.
abstract: Background The chronic and relapsing course of psoriasis is often associated with poor adherence to treatment. Adherence to topical treatment is abysmal. Adherence to systemic treatments also decreases over time, with an overall adherence rate of 67% for injectable biologic medications. Whereas overall trends in poor adherence have been documented, the fine details of adherence in individual patients is not well characterized. Purpose To assess adherence to adalimumab in patients with moderate to severe psoriasis. Methods Data on adherence were obtained from a 1-year open label trial including seven patients with moderate to severe psoriasis who agreed to participate in a randomized trial of standard physician education materials plus extended nurse education versus standard physician education materials alone. Adherence to treatment was recorded with electronic monitoring via Medication Event Monitoring System (MEMS) caps undisclosed to the patients. Patients were also instructed to note the time and date they used treatment in a journal. Results The subjects exhibited a broad range of adherence behaviors. Conclusions Adherence to adalimumab therapy for moderate-to-severe psoriasis is variable and can be very poor. The clinical impact of poor adherence to injectable biologic medications is not yet well characterized.
authors.forename: Cameron
authors.initials: C
authors.lastname: West
authors.forename: Swetha
authors.initials: S
authors.lastname: Narahari
authors.forename: Jenna
authors.initials: J
authors.lastname: O'Neill
authors.forename: Scott
authors.initials: S
authors.lastname: Davis
authors.forename: Monica
authors.initials: M
authors.lastname: Huynh
authors.forename: Adele
authors.initials: A
authors.lastname: Clark
authors.forename: Ann
authors.initials: A
authors.lastname: Boles
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D001688:Biological Products / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000295:instrumentation; D006801:Humans; D007279:Injections, Subcutaneous; D008499:Medical Records; D017744:Medical Waste Disposal / Q000295:instrumentation; D055118:Medication Adherence; D009339:Needles; D010353:Patient Education as Topic / Q000379:methods; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D017744:Medical Waste Disposal; D000068879:Adalimumab